Denosumab therapy and risk for severe hypocalcemia

Denosumab — marketed as Xgeva and as Prolia — is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream). Denosumab, when give as Xgeva,  is specifically indicated for the prevention of skeletal-related events in patients with bone metastases from prostate and other forms of cancer. … READ MORE …